1219000-33-5

Basic information

• Product Name: ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate
• Synonyms: ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate
• CAS NO: 1219000-33-5
• Molecular Weight: 563.068
• Mol File: 1219000-33-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate(1219000-33-5)
• EPA Substance Registry System: ((2R,3S,4R,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate(1219000-33-5)

Safety Data

• Hazardous Substances Data: 1219000-33-5(Hazardous Substances Data)

Upstream product

• 461432-26-8 dapagliflozin 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1219000-32-4 1-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-pyrrolidine-2-carboxylic acid methyl ester 
• 1219000-58-4 1-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1219000-69-7 (2R,3S,4R,5R,6S)-2-azidomethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol 
• 1219001-96-3 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(3-nitro-phenoxymethyl)-tetrahydro-pyran-3,4,5-triol 
• 1219002-01-3 3-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethoxy}-benzoic acid methyl ester 
• 1219000-38-0 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-((S)-2-hydroxymethyl-pyrrolidin-1-ylmethyl)-tetrahydro-pyran-3,4,5-triol 
• 1219000-35-7 1-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-pyrrolidine-2-carboxamide 
• 1219000-34-6 1-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-pyrrolidine-2-carboxylic acid 
• 1219000-70-0 (2R,3S,4R,5R,6S)-2-aminomethyl-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydro-pyran-3,4,5-triol 
• 1219000-68-6 1-{(2R,3S,4R,5R,6S)-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl}-3-ethyl-urea 
• 1219000-41-5 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(4-hydroxymethyl-[1,2,3]triazol-1-ylmethyl)-tetrahydro-pyran-3,4,5-triol 
• 1219000-42-6 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-(5-hydroxymethyl-[1,2,3]triazol-1-ylmethyl)-tetrahydro-pyran-3,4,5-triol 

Relevant articles and documents

SGLT-2 INHIBITORS

Provided are compounds of SGLT-2 inhibitors, pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with

GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.